Access to healthcare
Bringing health to the whole world
We aim to improve access to healthcare and deliver our medicines, services and education to patients around the world by tailoring our programmes to the communities they will serve. In some cases, this means looking at pricing; in others it involves overcoming other barriers to healthcare.
patients accessed hypertension education, screening and treatment through Healthy Heart Africa
Healthy Lung Asia in nine Asian markets
patients benefited from patient access programme
2017 SDG highlights
healthcare facilities activated
health professionals trained
of our sites have active employee well-being initiatives
Our access to healthcare strategy is made up of three elements:
- Expanding disease prevention, awareness and treatment
- Building capacity in areas with limited infrastructure
- Improving affordability and access to underserved patients
Healthcare is a universal right and extending access to healthcare is a global goal to which we can significantly contribute. We work with our industry and partners to remove barriers to access, not build them. Our in-depth understanding of the healthcare systems of emerging countries and healthcare needs of the people who live there has helped us develop our science-based strategy. We develop our programmes to best meet the needs of local communities. In some cases, this means looking at pricing; in others it involves overcoming other barriers to healthcare.
Young Health Programme
Launched in 2010, AstraZeneca’s Young Health Programme has reached 2.25 million young people with information, education and training about non-communicable disease risk factors. With our partners, we are training young people to share health information with their peers and frontline health providers in adolescent health.
Healthy Heart Africa
Nearly a third of African adults are estimated to have hypertension (high blood pressure). Our Healthy Heart Africa programme aims to support local health systems in Africa by increasing awareness of the symptoms and risks of hypertension, and by offering education, screening and reduced-cost treatment.
Healthy Lung Asia
In 2017, we launched the Healthy Lung Asia programme, focused on asthma, chronic obstructive pulmonary disease (COPD) and lung cancer in nine Asian markets. Our objective is to raise the profile of respiratory disease with policymakers and build health system capacity to support future services for patients.
Read more about our Community Investments and how they contribute to our Access to Healthcare Strategy here.
Early access to AstraZeneca investigational medicinal products
We recognise that there are circumstances where patients with serious or life-threatening diseases have exhausted all available therapeutic options and may not be eligible to enrol in one of our clinical trials. In such circumstances individual patients may be eligible for early access to an AstraZeneca investigational medicinal product.